Abstract
The proportion of transfused red blood cells (RBCs) that remain in circulation is an important surrogate marker of transfusion efficacy and contributes to predict the potential benefit of a transfusion process. Over the last 50 years, most of the transfusion recovery data were generated by chromium-51 (51Cr)-labeling studies and were predominantly performed to validate new storage systems and new processes to prepare RBC concentrates. As a consequence, our understanding of transfusion efficacy is strongly dependent on the strengths and weaknesses of 51Cr labeling in particular. Other methods such as antigen mismatch or biotin-based labeling can bring relevant information, for example, on the long-term survival of transfused RBC. These radioactivity-free methods can be used in patients including from vulnerable groups. We provide an overview of the methods used to measure transfusion recovery in humans, compare their strengths and weaknesses, and discuss their potential limitations. Also, based on our understanding of the spleen-specific filtration of damaged RBC and historical transfusion recovery data, we propose that RBC deformability and morphology are storage lesion markers that could become useful predictors of transfusion recovery. Transfusion recovery can and should be accurately explored by more than one method. Technical optimization and clarification of concepts is still needed in this important field of transfusion and physiology.
Highlights
Each year, more than 85 million red blood cells (RBCs) units are transfused worldwide
Recovery of autologous RBC in healthy non-anemic recipients using 51Cr labeling, 24 h after transfusion, is the method usu ally performed to determine the validity of the red cell concentrates (RCC) prepara tion/storage processes
Monocytes and macrophages, that possess a limited clearance capacity [80], could be saturated and leave in circulation dam aged RBC when a large volume of RBC is transfused. Such an assumption is supported by data showing that transfusion of more than five RCC leads to a decreased deformability of circulating RBC [81]
Summary
More than 85 million red blood cells (RBCs) units are transfused worldwide. This deman ding human and organizational task is conducted by national or local organizations. Transfusion recovery using chromium-51 (51Cr) labeling is a regulation criterion to license new storage systems or RCC preparation processes by the Food and Drug Administration (FDA). Over the last 50 years, most of the transfusion recovery data were generated by 51Cr-labeling studies, mostly to validate new storage systems and RCC preparation processes. We will provide a brief overview of the methods used to measure transfusion recovery in humans We will compare their strengths and weaknesses and critically analyze their potential limitations. Animal studies published in the recent years on this topic are beyond the scope of this analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.